Zacks Research Weighs in on GSK’s FY2024 Earnings (NYSE:GSK)

GSK plc (NYSE:GSK) – Analysts at Zacks Research increased their FY2024 EPS estimates for GSK in a research report issued to clients and investors on Tuesday, November 19th. Zacks Research analyst E. Bagri now forecasts that the pharmaceutical company will post earnings per share of $4.12 for the year, up from their prior estimate of $4.11. The consensus estimate for GSK’s current full-year earnings is $4.03 per share. Zacks Research also issued estimates for GSK’s Q1 2026 earnings at $1.14 EPS and Q3 2026 earnings at $1.57 EPS.

A number of other brokerages have also weighed in on GSK. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and reduced their target price for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Argus upgraded GSK to a “strong-buy” rating in a report on Wednesday, August 7th. Barclays upgraded GSK to a “hold” rating in a research note on Tuesday, August 27th. Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Finally, Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Seven research analysts have rated the stock with a hold rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Stock Up 1.0 %

Shares of NYSE:GSK opened at $33.67 on Friday. The company has a 50 day moving average price of $38.27 and a two-hundred day moving average price of $40.44. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. The company has a market capitalization of $69.79 billion, a PE ratio of 21.87, a PEG ratio of 1.29 and a beta of 0.66. GSK has a 52 week low of $32.83 and a 52 week high of $45.92.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Pitcairn Co. bought a new position in GSK in the 1st quarter valued at approximately $386,000. CreativeOne Wealth LLC bought a new position in shares of GSK during the first quarter valued at $235,000. EP Wealth Advisors LLC lifted its holdings in shares of GSK by 24.8% during the first quarter. EP Wealth Advisors LLC now owns 13,846 shares of the pharmaceutical company’s stock worth $594,000 after purchasing an additional 2,755 shares during the period. Advisors Asset Management Inc. grew its stake in shares of GSK by 5.8% in the first quarter. Advisors Asset Management Inc. now owns 119,736 shares of the pharmaceutical company’s stock worth $5,133,000 after purchasing an additional 6,559 shares during the last quarter. Finally, 1832 Asset Management L.P. increased its holdings in GSK by 9.1% in the first quarter. 1832 Asset Management L.P. now owns 3,078 shares of the pharmaceutical company’s stock valued at $132,000 after purchasing an additional 257 shares during the period. 15.74% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at GSK

In other GSK news, major shareholder Plc Gsk bought 2,791,930 shares of the stock in a transaction dated Friday, September 27th. The shares were bought at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the acquisition, the insider now owns 16,775,691 shares of the company’s stock, valued at $134,205,528. This trade represents a 19.97 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 10.00% of the stock is currently owned by corporate insiders.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, January 9th. Investors of record on Friday, November 15th will be issued a dividend of $0.3928 per share. This is a boost from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 annualized dividend and a yield of 4.67%. The ex-dividend date of this dividend is Friday, November 15th. GSK’s dividend payout ratio (DPR) is presently 98.70%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.